Aripiprazole Augmentation in an 86-Year-Old on Duloxetine: Not Recommended
In this 86-year-old long-term-care patient on duloxetine 30 mg twice daily, adding aripiprazole (Abilify) as adjunctive therapy for major depressive disorder is not recommended due to significant safety concerns specific to this patient's age and medication regimen.
Key Safety Concerns in This Specific Case
Drug-Drug Interaction Risk
The combination of duloxetine and aripiprazole creates a clinically significant pharmacokinetic interaction. Duloxetine inhibits CYP2D6, leading to 54.2% higher aripiprazole plasma concentrations and 45.6% higher dose-adjusted concentrations 1. This interaction is dose-dependent, with higher duloxetine doses (this patient is on 60 mg/day total) producing greater aripiprazole accumulation 1. The FDA label specifies that when aripiprazole is combined with strong CYP2D6 inhibitors like duloxetine, the aripiprazole dose must be reduced to half the usual dose 2.
Age-Related Safety Issues
At 86 years old, this patient faces substantially elevated risks:
Falls and fractures: Antipsychotics in older adults significantly increase fall risk. The 2019 AGS Beers Criteria® strongly recommends avoiding antipsychotics in older adults due to increased mortality and cerebrovascular events 3. In the OPTIMUM trial of older adults (mean age 69), falls were a prominent adverse event with aripiprazole augmentation 4.
Akathisia and Parkinsonism: In the landmark geriatric depression trial, 26% of patients on aripiprazole developed akathisia and 17% developed Parkinsonism 5. These movement disorders are particularly problematic in frail elderly patients and increase fall risk.
Cognitive impairment: Antipsychotics can worsen cognition and cause delirium in older adults 6.
Alternative Strategies to Consider First
Optimize Current Antidepressant
The patient is on duloxetine 30 mg twice daily (60 mg total). Guidelines recommend 6-8 weeks at an adequate dose before considering augmentation 7. Duloxetine can be dosed up to 120 mg/day 8, so increasing to 60 mg twice daily (120 mg total) may be appropriate if tolerated and if the current dose has been inadequate for 6-8 weeks.
Switch Antidepressants
For older adults, preferred antidepressants include escitalopram, sertraline, mirtazapine, venlafaxine, and bupropion 9. Switching to one of these alternatives is safer than adding an antipsychotic in this age group. The American College of Physicians guidelines support switching if inadequate response after 6-8 weeks 7.
Non-Pharmacological Approaches
Before escalating to antipsychotic augmentation, ensure psychotherapy (particularly cognitive behavioral therapy) has been considered, as it is effective for depression and carries no medication risks 7.
If Aripiprazole Must Be Used
Should clinical circumstances absolutely require aripiprazole augmentation despite these concerns:
Reduce dose by 50%: Start at 2 mg daily (not the standard 5 mg) due to the duloxetine interaction 2. Maximum dose should not exceed 7.5 mg daily.
Monitor intensively for:
- Akathisia (restlessness, inability to sit still) - occurs in first 3 weeks in 76% of cases 10
- Parkinsonism (tremor, rigidity, shuffling gait)
- Falls and orthostatic hypotension
- Sedation and cognitive changes
- Weight gain and metabolic effects
Assess within 1-2 weeks of initiation 7.
Plan for short-term use only: If effective, attempt discontinuation after 4-9 months of remission 7. There is no evidence supporting long-term antipsychotic use in depression 11.
Consider levetiracetam interaction: While not extensively studied, monitor for increased sedation with this combination.
Evidence Quality Assessment
The recommendation against aripiprazole in this case is based on:
- Strong guideline evidence from AGS Beers Criteria® against antipsychotics in older adults 3
- High-quality RCT data showing significant movement disorder risks in geriatric depression 5
- Pharmacokinetic study demonstrating clinically significant duloxetine-aripiprazole interaction 1
- FDA labeling requiring dose adjustment with CYP2D6 inhibitors 2
While aripiprazole augmentation shows efficacy in treatment-resistant depression (NNT 6.6 in older adults 5), the 86-year-old age, duloxetine interaction, and fall risk in a long-term-care setting shift the risk-benefit ratio unfavorably.